QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
NASDAQ:CRNX

Crinetics Pharmaceuticals - CRNX Stock Forecast, Price & News

$19.10
-1.30 (-6.37%)
(As of 01/30/2023 04:20 PM ET)
Add
Compare
Today's Range
$18.99
$20.22
50-Day Range
$15.49
$21.10
52-Week Range
$15.37
$27.86
Volume
299,490 shs
Average Volume
434,678 shs
Market Capitalization
$1.03 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.00

Crinetics Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
118.3% Upside
$42.00 Price Target
Short Interest
Bearish
6.94% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.57mentions of Crinetics Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$396,210 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.14) to ($3.26) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

794th out of 1,049 stocks

Pharmaceutical Preparations Industry

397th out of 514 stocks


CRNX stock logo

About Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Receive CRNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRNX Stock News Headlines

"We need batteries. Literally everywhere."
Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense."
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
CRNX Crinetics Pharmaceuticals, Inc.
CRNX Crosses Above Key Moving Average Level
See More Headlines
Receive CRNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRNX Company Calendar

Last Earnings
11/14/2022
Today
1/30/2023
Next Earnings (Estimated)
3/29/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRNX
Fax
N/A
Employees
143
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$42.00
High Stock Price Forecast
$45.00
Low Stock Price Forecast
$39.00
Forecasted Upside/Downside
+119.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-107,640,000.00
Net Margins
-2,932.26%
Pretax Margin
-2,912.48%

Debt

Sales & Book Value

Annual Sales
$1.08 million
Book Value
$6.99 per share

Miscellaneous

Free Float
50,582,000
Market Cap
$1.03 billion
Optionable
Not Optionable
Beta
0.97

Key Executives

  • Scott R. Struthers
    President, Chief Executive Officer & Director
  • Jeff E Knight
    Chief Operating Officer
  • Marc J. S. Wilson
    Chief Financial Officer
  • Stephen F. BetzStephen F. Betz
    Chief Scientific Officer
  • Alan Seth Krasner
    Chief Medical Officer













CRNX Stock - Frequently Asked Questions

Should I buy or sell Crinetics Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRNX shares.
View CRNX analyst ratings
or view top-rated stocks.

What is Crinetics Pharmaceuticals' stock price forecast for 2023?

3 Wall Street analysts have issued 12 month target prices for Crinetics Pharmaceuticals' stock. Their CRNX share price forecasts range from $39.00 to $45.00. On average, they predict the company's stock price to reach $42.00 in the next twelve months. This suggests a possible upside of 117.5% from the stock's current price.
View analysts price targets for CRNX
or view top-rated stocks among Wall Street analysts.

How have CRNX shares performed in 2023?

Crinetics Pharmaceuticals' stock was trading at $18.30 at the beginning of 2023. Since then, CRNX shares have increased by 5.5% and is now trading at $19.31.
View the best growth stocks for 2023 here
.

When is Crinetics Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our CRNX earnings forecast
.

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) announced its earnings results on Monday, November, 14th. The company reported ($0.78) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.78). The business earned $0.46 million during the quarter, compared to the consensus estimate of $1 million. Crinetics Pharmaceuticals had a negative trailing twelve-month return on equity of 43.63% and a negative net margin of 2,932.26%.

What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO?

6 employees have rated Crinetics Pharmaceuticals Chief Executive Officer R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among the company's employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 68.0% of employees surveyed would recommend working at Crinetics Pharmaceuticals to a friend.

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

When did Crinetics Pharmaceuticals IPO?

(CRNX) raised $80 million in an IPO on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray acted as the underwriters for the IPO.

What is Crinetics Pharmaceuticals' stock symbol?

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

Who are Crinetics Pharmaceuticals' major shareholders?

Crinetics Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bourgeon Capital Management LLC (0.00%), Psagot Value Holdings Ltd. Israel (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ajay Madan, Jeff E Knight, Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers, Stephen F Betz and Vivo Capital Viii, Llc.
View institutional ownership trends
.

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Crinetics Pharmaceuticals' stock price today?

One share of CRNX stock can currently be purchased for approximately $19.31.

How much money does Crinetics Pharmaceuticals make?

Crinetics Pharmaceuticals (NASDAQ:CRNX) has a market capitalization of $1.04 billion and generates $1.08 million in revenue each year. The company earns $-107,640,000.00 in net income (profit) each year or ($3.00) on an earnings per share basis.

How many employees does Crinetics Pharmaceuticals have?

The company employs 143 workers across the globe.

How can I contact Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The official website for the company is www.crinetics.com. The company can be reached via phone at (858) 450-6464 or via email at ir@crinetics.com.

This page (NASDAQ:CRNX) was last updated on 1/30/2023 by MarketBeat.com Staff